Bachem Holding AG: Trading Activity and Strategic Developments
Market Performance
- Current price: CHF 84.15 per share on the SIX Swiss Exchange.
- 24‑hour movement: Up 2.99 % as of 08:02 PM Central Europe on Wednesday 21 March.
- Volume: CHF 12.7 million worth of shares traded in the last 24 hours.
- Market capitalisation: CHF 6.5 billion.
- Shares outstanding: 75 million.
- Simple moving average (200 days): CHF 71.44.
- 52‑week high: CHF 86.00 (recorded 20 October 2026).
- 52‑week low: CHF 48.52 (recorded 19 November 2025).
- Month‑end performance: Up 6.44 % since the previous month’s end.
Strategic Context
Bachem Holding AG has been actively involved in the early‑stage development of white‑label platforms designed to support the forthcoming overhaul of private pension schemes. Two financial news reports highlighted this engagement, citing interviews with key executives:
- Max Bachem, founder and CEO, discussed the company’s perception of regulatory changes and potential benefits.
- Steffen Orlowski, head of IFA & Insurance, elaborated on how the new pension framework could increase competition and create opportunities for Bachem’s platform offerings.
While the reports did not disclose specific financial impacts, they emphasized Bachem’s proactive stance and readiness to capitalize on the evolving private pension landscape.
Comparative Stock Performance (Last 24 Hours)
| Symbol | 24‑hour change | Current price (CHF) | Market cap (CHF bn) | P/E ratio |
|---|---|---|---|---|
| GRKP.SW (Graubuendner Kantonalbank) | 0 % | 2,600 | 6.5 | 19.81 |
| SUN.SW (Sulzer) | –0.86 % | 175.9 | 5.9 | 19.46 |
| ACLN.SW (Accelleron Industries) | –2.63 % | 68 | 6.4 | 40.06 |
| BARN.SW (Barry Callebaut) | +0.09 % | 1,165 | 6.3 | 26.10 |
| AVOL.SW (Avolta) | –0.75 % | 45.34 | 6.1 | 31.06 |
Notable Historical Data
- Sulzer: Shares bought at CHF 91.45 (5 years ago) would have appreciated to CHF 172.60 by 20 October 2026, yielding a portfolio value of CHF 1,887 for a CHF 1,000 investment.
- Accelleron Industries: Completed a comprehensive, automated, secure global IT infrastructure using Cisco Catalyst Center, ThousandEyes, and Cisco networking solutions. The upgrade enhances operational resilience across more than 50 countries and two main production sites.
Company Overview
Bachem Holding AG, headquartered in Bubendorf, Switzerland, specialises in the development and manufacture of peptides and oligonucleotides. The company supplies research, clinical development, and commercial products to pharmaceutical and biotechnology firms worldwide. Shares are listed on the SIX Swiss Exchange; further information is available on the company’s website at www.bachem.ch .
